Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and Drug Administration approval last month.

has approved the first prescription medication specifically for treating obstructive sleep apnea (OSA): the weight-loss drug Zepbound. In a news release published Dec. 20, the FDA stated that ...

The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in adults with obesity, the drugmaker Eli Lilly said Friday. The decision makes ...

Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.

Both of these GLP-1 drugs were originally designed for diabetes, but their benefits keep expanding — KSTP health expert Dr.

Zepbound is an injectable prescription medication created to help adults with obesity and weight-related problems, including obstructive sleep apnea. OSA causes airway collapses during sleep and ...

Teens and young adults with anxiety, ADHD, or sleep disorders were more likely to have a diagnosis of addiction to sedatives ...

SURMOUNT-OSA trials: Zepbound reduced apnea events by 62.8%, improving sleep apnea outcomes. CMS spokesperson said that Medicare Part D can only cover obesity drugs if they are FDA-approved for ...

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, broadening access to the blockbuster weight-loss treatment. The Wednesday ...